SCHEMBL1640299

SCHEMBL1640299

CN(C)C1Cc2ccc(Nc3nccc(-c4sc(N)nc4-c4cccc(NC(=O)c5c(F)cccc5F)c4)n3)cc2C1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 4/20 0.60
▸ IGF1R P08069 8/20 0.50
▸ EGFR P00533 7/20 0.50
▸ ERBB2 P04626 6/20 0.50
▸ KDR P35968 3/20 0.48
▸ AURKB Q96GD4 3/20 0.48
▸ AURKA O14965 2/20 0.48
▸ CDK19 Q9BWU1 1/20 0.48
▸ PKMYT1 Q99640 1/20 0.48
▸ SLC2A1 P11166 4/20 0.46
▸ PRKD3 O94806 2/20 0.46
▸ MAP4K4 O95819 2/20 0.46
▸ LCK P06239 2/20 0.46
▸ FYN P06241 2/20 0.46
▸ CSF1R P07333 2/20 0.46
▸ RET P07949 2/20 0.46
▸ MAP4K2 Q12851 2/20 0.46
▸ STK3 Q13188 2/20 0.46
▸ TAOK1 Q7L7X3 2/20 0.46
▸ MAP4K5 Q9Y4K4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12726225 0.85 BRAF (0.82) BRAFIGF1REGFRERBB2KDR
SCHEMBL12726212 0.84 BRAF (0.58) BRAFIGF1REGFRERBB2KDR
SCHEMBL1644028 0.84 AURKA (0.68) BRAFIGF1REGFRERBB2KDR
SCHEMBL1641702 0.82 BRAF (0.54) BRAFIGF1REGFRERBB2KDR
SCHEMBL1789515 0.82 BRAF (0.74) BRAFIGF1REGFRERBB2KDR
SCHEMBL12726205 0.81 SLC2A1 (0.67) BRAFIGF1REGFRERBB2KDR
SCHEMBL1640303 0.81 IGF1R (0.55) BRAFIGF1REGFRERBB2KDR
SCHEMBL3442188 0.81 KDR (0.74) BRAFIGF1REGFRERBB2KDR
SCHEMBL12726228 0.81 BRAF (0.61) BRAFIGF1REGFRERBB2KDR
SCHEMBL1641673 0.81 BRAF (0.68) BRAFIGF1REGFRERBB2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 — — US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 — — US disclosed
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors GLAXOSMITHKLINE LLC 2011-04-28 — — US disclosed
WO-2009076140-A1 THIAZOLE AND OXAZOLE KINASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098296-A1 Thiazole And Oxazole Kinase Inhibitors PDXK, MAP3K1, MAP4K2 BRAF 151/4885IGF1R 396/4885EGFR 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback